Description
What is Retatrutide?
Retatrutide (LY3437943) is a synthetic peptide that acts as an agonist at the GIP, GLP-1 and glucagon receptors. It is studied in receptor-signalling and metabolic research. Published findings about the compound do not verify the identity, purity or performance of an individual supplied batch.
Published study findings and evidence limits
Human trial evidence
A placebo-controlled phase 2 trial in adults with obesity reported greater body-weight reduction with retatrutide over 48 weeks. Gastrointestinal adverse effects and increases in heart rate were reported. These results concern the trial formulation and study population, not this supplied research material.
Sources: Retatrutide obesity trial (2023).
Are benefits proven for this product? No clinical benefit has been established for the research material sold in this listing. Positive results for a characterised study formulation do not validate this batch, its safety or its suitability for human use. Research findings are provided for scientific context.
For research purposes only. Supplied exclusively for laboratory research and analytical use. Not for human or animal consumption, injection, therapeutic, diagnostic or cosmetic use. This product is not supplied as a medicine, food or dietary supplement. Information on this page describes research context and does not establish safety or efficacy for use in people or animals.
Reviews
There are no reviews yet.